Nuvilex (NASDAQ:PMCB) Raised to Sell at Wall Street Zen

Nuvilex (NASDAQ:PMCB) was upgraded by equities researchers at Wall Street Zen to a “sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Nuvilex in a research report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Nuvilex Price Performance

NASDAQ PMCB opened at $0.82 on Friday. The company has a market cap of $8.30 million, a P/E ratio of -0.59 and a beta of 0.04. The stock has a 50-day moving average of $0.87 and a two-hundred day moving average of $0.92. Nuvilex has a 1-year low of $0.63 and a 1-year high of $1.90.

Nuvilex (NASDAQ:PMCB) last posted its quarterly earnings data on Thursday, December 18th. The company reported ($0.32) EPS for the quarter.

Insiders Place Their Bets

In other news, CEO Joshua Silverman bought 40,000 shares of Nuvilex stock in a transaction that occurred on Wednesday, January 7th. The shares were purchased at an average price of $0.83 per share, with a total value of $33,200.00. Following the completion of the acquisition, the chief executive officer directly owned 416,250 shares in the company, valued at $345,487.50. The trade was a 10.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have purchased a total of 110,000 shares of company stock valued at $89,000 over the last 90 days. 10.33% of the stock is owned by company insiders.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.